Investment in Cenovus Energy	3 Months Ended
Mar. 31, 2021
Investment In Cenovus Energy [Abstract]
Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]	Note 5-–Investment in Cenovus Energy In 2017, we completed the sale of certain assets to Cenovus Energy (CVE) in which we received 208 million CVE common shares as consideration. At March 31, 2021, the investment was included on our consolidated balance sheet at fair value of $ 1.56 billion, which approximates 10.3 percent of the issued and outstanding CVE common stock. The fair value of the 208 million CVE common shares reflects the closing price of $ 7.52 per share on the NYSE on the last trading day of the quarter. In the first quarter of 2021, we recognized an unrealized gain of $ 308 million before-tax on our CVE common shares, compared with an unrealized loss of $ 1,691 million before-tax in the first quarter of 2020. The unrealized gain (loss) associated with changes in fair value are reflected within the “Other income (loss)” line on our consolidated income statement in the first quarter of 2021 relating to the shares held at the reporting date. See Note 11—Fair Value Measurement for additional information. Subject to market conditions, we intend to decrease our investment over time through market transactions, private agreements or otherwise.

Investment in Cenovus Energy

3 Months Ended

Mar. 31, 2021

Note 5-–Investment in Cenovus Energy

In 2017, we completed the sale of certain assets

to Cenovus Energy (CVE) in which we received

208

million

CVE common shares as consideration.

At March 31, 2021, the investment was included

on our consolidated

balance sheet at fair value of $

1.56

billion, which approximates

10.3

percent of the issued and outstanding

CVE common stock.

The fair value of the

208

million CVE common shares reflects the

closing price of $

7.52

per share on the NYSE on the last trading day

of the quarter.

In the first quarter of 2021, we recognized an

unrealized gain of $

308

million before-tax on our CVE common shares,

compared with an unrealized loss of

1,691

million before-tax in the first quarter

of 2020.

The unrealized gain (loss) associated with changes

fair value are reflected within the “Other income

(loss)” line on our consolidated income statement

in the first

quarter of 2021 relating to the shares held at the

reporting date.

See Note 11—Fair Value Measurement for

additional information.

Subject to market conditions, we intend to

decrease our investment over time through

market transactions, private agreements or otherwise.